









Markets
/
Stocks
/
nasdaq-gdtc
/

CytoMed Therapeutics Ltd

GDTC

2.110USD

+0.120+6.03%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

24.33MMarket Cap

--P/E TTM



CytoMed Therapeutics Ltd

2.110

+0.120+6.03%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of CytoMed Therapeutics Ltd

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is relatively high. Over the past 30 days, multiple analysts have rated the company as a . The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CytoMed Therapeutics Ltd's Score

Industry at a Glance

Industry Ranking

309 / 501

Overall Ranking

625 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

5.000

Target Price

+143.90%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

CytoMed Therapeutics Ltd Highlights

StrengthsRisks

CytoMed Therapeutics Limited is a biopharmaceutical company. It is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT, and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The CTM-GDT product candidate consists of expanded allogeneic gamma delta T cells.

Growing

The company is in a growing phase, with the latest annual income totaling USD 53.12K.

Undervalued

The company’s latest PE is -15.15, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 50.10K shares, increasing 13.97% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

CytoMed Therapeutics Ltd's Company Valuation

Currency: USD Updated: 2025-10-27

There is no valuation score for this company; the Biotechnology & Medical Research industry's average is 6.98. Its current P/E ratio is -15.15, which is -100.00% below the recent high of 0.00 and -70.71% above the recent low of -25.86.

Score

Industry at a Glance

Previous score

0.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 309/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.04. The average price target for CytoMed Therapeutics Ltd is 5.00, with a high of 5.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 7.07, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 3.44 and the support level at 1.65, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.04

Change

0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.105

Neutral

RSI(14)

46.295

Neutral

STOCH(KDJ)(9,3,3)

19.777

Buy

ATR(14)

0.294

High Vlolatility

CCI(14)

-93.746

Neutral

Williams %R

89.205

Oversold

TRIX(12,20)

0.282

Sell

StochRSI(14)

70.102

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

2.113

Sell

MA10

2.238

Sell

MA20

2.280

Sell

MA50

2.111

Sell

MA100

2.061

Buy

MA200

2.256

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Glorious Finance Limited

3.77M

mDR Limited

1.22M

-8.63%

Wang (Shu)

883.86K

28 Consultants Ltd

880.31K

+23.12%

Jieming (Zeng)

589.24K

Choo (Chee Kong)

598.01K

Citadel Advisors LLC

27.67K

+60.40%

UBS Financial Services, Inc.

17.58K

+21.69%

Geode Capital Management, L.L.C.

4.85K

Tower Research Capital LLC

-100.00%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.